Cipher Pharmaceuticals (OTCMKTS:CPHRF – Get Free Report) (TSE:CPH) is anticipated to release its resultson Thursday, August 6th. Analysts expect the company to post earnings of $0.2063 per share and revenue of $13.6060 million for the quarter.
Cipher Pharmaceuticals Stock Down 0.5%
CPHRF stock opened at $11.60 on Thursday. Cipher Pharmaceuticals has a fifty-two week low of $8.64 and a fifty-two week high of $15.00. The business has a 50-day moving average of $11.80 and a 200-day moving average of $11.92.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company that develops, acquires and commercializes prescription products in respiratory and dermatology markets. Founded in 2004 and headquartered in Vancouver, British Columbia, the company focuses on in-licensing established therapies and launching them under its own commercial infrastructure in North America.
In the respiratory segment, Cipher markets generic inhalation therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Read More
- Five stocks we like better than Cipher Pharmaceuticals
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
